Rabinowitz Deborah, Dysart Kevin, Itkin Maxim
Division of Interventional Radiology, Department of Medical Imaging, Nemours Children's Hospital, Delaware, Wilmington, Delaware.
Department of Radiology and Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
Curr Opin Pediatr. 2022 Apr 1;34(2):191-196. doi: 10.1097/MOP.0000000000001109.
Neonatal lymphatic disorders (NLDs) are conditions that are relatively rare and difficult to treat. The recent development of lymphatic imaging, such as Dynamic Contrast-Enhanced MR Lymphangiography and Intranodal Lymphangiography has led to a new, better understanding of the anatomical substrate and pathophysiological mechanisms of the diseases. Consequently, this has allowed the development of new targeted therapeutic interventions as well as prognostication for this population with lymphatic flow disorders.
The underlying causes of all NLD is an obstruction or altered flow of the central lymphatic flow. Two types of NLD have been described: isolated neonatal chylothorax and central lymphatic flow disorder (CLFD). Isolated neonatal chylothorax can be treated successfully with oil-based contrast (lipiodol) embolization. CLFD secondary to obstruction of the thoraco-venous junction can be successfully treated with surgical thoracic duct-venous anastomosis. CLFD caused by elevated central pressure and/or thoracic duct dysplasia can be treated medically, including with new systemic therapies such as mammalian target of rapamycin inhibitors.
New diagnostic and interventional tools have recently allowed for classification, prognostication, and targeted interventions for neonatal patients with lymphatic flow disorders. Further research will build on these discoveries.
新生儿淋巴系统疾病(NLDs)相对罕见且治疗困难。淋巴成像技术的最新发展,如动态对比增强磁共振淋巴造影和淋巴结内淋巴管造影,使人们对这些疾病的解剖学基础和病理生理机制有了新的、更好的认识。因此,这使得针对该淋巴液流动障碍人群的新的靶向治疗干预措施以及预后评估得以发展。
所有NLD的根本原因是中央淋巴液流动受阻或改变。已描述了两种类型的NLD:孤立性新生儿乳糜胸和中央淋巴液流动障碍(CLFD)。孤立性新生儿乳糜胸可用油基造影剂(碘油)栓塞成功治疗。继发于胸静脉交界处梗阻的CLFD可通过手术胸导管-静脉吻合术成功治疗。由中心压力升高和/或胸导管发育异常引起的CLFD可采用药物治疗,包括使用新的全身疗法,如雷帕霉素靶蛋白抑制剂。
新的诊断和介入工具最近已可用于对患有淋巴液流动障碍的新生儿患者进行分类、预后评估和靶向干预。进一步的研究将基于这些发现展开。